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Potentiation of inhibition of wild-type and mutant human
immunodeficiency virus type 1 reverse transcriptases by
combinations of nonnucleoside inhibitors and d- and
L-(beta)-dideoxynucleoside triphosphate analogs
Abstract
Combinations of reverse transcriptase (RT) inhibitors are currently used in anti-human
immunodeficiency virus therapy in order to prevent or delay the emergence of resistant virus and to
improve the efficacy against viral enzymes carrying resistance mutations. Drug-drug interactions can
result in either positive (additive or synergistic inhibition) or adverse (antagonistic interaction,
synergistic toxicity) effects. Elucidation of the nature of drug interaction would help to rationalize the
choice of antiretroviral agents to be used in combination. In this study, different combinations of
nucleoside and nonnucleoside inhibitors, including D- and L-(beta)-deoxy- and -dideoxynucleoside
triphosphate analogues, have been tested in in vitro RT assays against either recombinant wild-type RT
or RT bearing clinically relevant nonnucleoside inhibitor resistance mutations (L100I, K103N, Y181I),
and the nature of the interaction (either synergistic or antagonistic) of these associations was evaluated.
The results showed that (i) synergy of a combination was not always equally influenced by the
individual agents utilized, (ii) a synergistic combination could improve the sensitivity profile of a
drug-resistant mutant enzyme to the single agents utilized, (iii) L-(beta)-enantiomers of nucleoside RT
inhibitors were synergistic when combined with nonnucleoside RT inhibitors, and (iv) inter- and
intracombination comparisons of the relative potencies of each drug could be used to highlight the
different contributions of each drug to the observed synergy.
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Combinations of reverse transcriptase (RT) inhibitors are currently used in anti-human immunodeficiency
virus therapy in order to prevent or delay the emergence of resistant virus and to improve the efficacy against
viral enzymes carrying resistance mutations. Drug-drug interactions can result in either positive (additive or
synergistic inhibition) or adverse (antagonistic interaction, synergistic toxicity) effects. Elucidation of the
nature of drug interaction would help to rationalize the choice of antiretroviral agents to be used in combi-
nation. In this study, different combinations of nucleoside and nonnucleoside inhibitors, including D- and
L-(b)-deoxy- and -dideoxynucleoside triphosphate analogues, have been tested in in vitro RT assays against
either recombinant wild-type RT or RT bearing clinically relevant nonnucleoside inhibitor resistance muta-
tions (L100I, K103N, Y181I), and the nature of the interaction (either synergistic or antagonistic) of these
associations was evaluated. The results showed that (i) synergy of a combination was not always equally
influenced by the individual agents utilized, (ii) a synergistic combination could improve the sensitivity profile
of a drug-resistant mutant enzyme to the single agents utilized, (iii) L-(b)-enantiomers of nucleoside RT
inhibitors were synergistic when combined with nonnucleoside RT inhibitors, and (iv) inter- and intracombi-
nation comparisons of the relative potencies of each drug could be used to highlight the different contributions
of each drug to the observed synergy.
The majority of the drugs currently utilized for the clinical
treatment of human immunodeficiency virus type 1 (HIV-1)-
infected individuals are targeted against the viral reverse tran-
scriptase (RT), the enzyme responsible for the conversion of
viral genomic single-stranded RNA into double-stranded pro-
viral DNA (2, 21, 22). These drugs can be divided into two
broad classes: (i) dideoxynucleoside analogues (or nucleoside
RT inhibitors [NRTIs]), such as zidovudine (39-azido-29,39-
dideoxythymidine) (AZT), zacitalbine (29,39-dideoxycytidine)
(ddC), didanosine (29,39-dideoxyinosine) (ddI), stavudine
(29,39-didehydro-29,39-dideoxythymidine) (d4T), lamivudine
[(2)-b-L-29-deoxy-39-oxa-49-thiocytidine] (3TC), and abacavir,
which inhibit viral replication by acting in their triphosphate
form as chain terminators of DNA synthesis, and (ii) non-
nucleoside analogues (or nonucleoside RT inhibitors [NNR-
TIs]), including structurally different molecules, such as nevi-
rapine, delavirdine, and efavirenz, which bind to a common
allosteric site of RT distinct from the polymerase active site,
thus inhibiting catalysis. Due to the emergence of drug resis-
tance mutations in the RT gene, which is readily accomplished
in vivo due to the low fidelity of RT and the massive viral
turnover, all these drugs showed a significant but limited and
transient beneficial effect on inhibition of viral replication
when administered in monotherapy regimens. In addition,
many of the selected mutations display cross-resistance to
other NRTIs and NNRTIs (23, 29). Multiple drug combina-
tions have been shown to suppress viral load for relatively
longer periods of time compared to monotherapy (2, 10). Com-
bination therapy could allow administration of lower dosages
of individual drugs than monotherapy regimens, thus limiting
the toxic side effects, and it could result in potentiation of their
therapeutic efficacy due to synergism among the different com-
pounds administered. Indeed, several studies reported syner-
gistic activities for different combinations of NRTIs with
NNRTIs and even of NNRTIs with NNRTIs (4, 9, 10, 19, 30,
31, 35, 37, 39). Combination of drugs does not always result in
beneficial effects, and several examples have been reported of
antagonistic activity, increased toxicity, and metabolic interfer-
ence as well as increased drug resistance mutation rates for
certain drug associations (2, 10). An additional important fac-
tor affecting the interaction between RT inhibitors in vivo is
the heterogeneity of the viral population, where mutant virus
strains which exhibit reduced susceptibility to RT inhibitors are
present. Thus, expanding knowledge of the efficacy of RT
inhibitor combinations against viral enzymes carrying resis-
tance mutations to one or more of the utilized drugs would
allow a better prediction of the in vivo outcome of the combi-
nations. The evaluation of positive (synergistic) or negative
(antagonistic) effects of combinations of RT inhibitors could
be incorporated into screening programs for new drugs. Such
approaches would allow the characterization of the efficacy of
* Corresponding author. Mailing address: Istituto di Genetica Bio-
chimica ed Evoluzionistica—CNR, I-27100 Pavia, Italy. Phone: 39-
0382546355. Fax: 39-0382422286. E-mail: maga@igbe.pv.cnr.it.
1192
a new RT inhibitor in terms of its favorable (i.e., synergistic)
action with other drugs in suppressing HIV-1 RT activity. Syn-
ergy assessment has been performed in the majority of inves-
tigations using infected-cell-based assays. However, in complex
biological systems such as infected cells, it is very difficult to
determine the precise mechanisms of any observed drug-drug
interaction. Moreover, the impossibility of knowing the exact
concentration of the drug within the cell prevents any detailed
enzymological study of the interaction of different inhibitors at
the level of their molecular target(s). Enzymatic assays em-
ploying purified enzymes are more suitable for kinetic studies,
and indeed some detailed enzymological analyses of drug-drug
interaction using such approaches have been published (5, 7,
15, 28, 36, 39). In many cases good correspondence between the
results obtained with enzymatic assays and infected-cell-based
assays has been found (7, 15, 39), even if the behavior of the drugs
used in the combinations can be influenced by the reaction con-
ditions (1, 6, 37). In the present work, different combinations of
NRTIs and NNRTIs have been tested against recombinant RTs,
either wild type (wt) or bearing clinically relevant NNRTI resis-
tance mutations. It has been shown that the compound 3TC, with
the unnatural L-(b)- conformation, selected for uncommon resis-
tance mutations at Met184 of RT which were able to restore AZT
sensitivity when expressed in a resistant genetic background (33).
Since other L-(b)-NRTIs, such as L-(b)-ddC and -(2)-b-L-29-de-
oxy-39-oxa-49-thiocytidine (dOTC), have been shown to potently
inhibit as triphosphates HIV-1 RT as well as virus replication in
infected cells (13, 16, 26, 27, 35), we wanted to further investigate
the interaction of L-(b)-NRTIs with other NRTIs and NNRTIs.
We have focused our attention on the clinically used NNRTIs
nevirapine and efavirenz. In particular for efavirenz, the synergis-
tic effects of its combination with D- and L-(b)-dideoxynucleoside
triphosphate analogues were studied since, in spite of a large body
of data about efavirenz’s clinical use in combination with AZT
and 3TC, there are few detailed studies on the nature of its
interaction with NRTIs (38). Recently, our group identified a
specific mechanism of action for efavirenz, which might suggest a
possible synergistic action of this compound in combination with
other NNRTIs (28). Thus, the effect of efavirenz association with
nevirapine and nevirapine plus AZT was also studied. Our results
highlight the different natures of the interactions among these
drugs and suggest that the use of synergistic NRTI-NNRTI com-
binations could also be effective against NNRTI-resistant mutants
and that L-(b)-dideoxynucleoside triphosphate analogues are syn-
ergistic when used in combination with NRTIs and NNRTIs in
place of the corresponding D-enantiomers.
MATERIALS AND METHODS
Chemicals. [3H]29,39-deoxythymidine triphosphate (dTTP) (40 Ci/mmol) was
from Amersham, and unlabeled deoxynucleoside triphosphates (dNTPs) and
ddNTPs were from Boehringer. Whatman was the supplier of the GF/C filters.
All other reagents were of analytical grade and were purchased from Merck or
Fluka. Efavirenz has been synthesized according to procedures of L. Tan et al.
(34). The final preparation showed the following physicochemical properties. mp
133 to 136°C (hexane/toluene). High-performance liquid chromatography anal-
ysis: RT 5 6.57 min. 1H NMR (CDCl3)_: 0.85, (m, 2H), 0.94 (m, 2H), 1.40 (m,
1H), 6.81 (d, J 5 8.5 Hz, 1H), 7.37 (dd, J 5 2.5, 8.5 Hz, 1H), 7.49 (d, J 5 2.5 Hz,
1H), 8.71 (br s, 1H). 13C NMR 148.0, 133.2, 131.6, 129.0, 127.8, 127.7, 123.9,
120.1, 116.3, 115.7, 95.8, 77.3, 77.1, 76.9, 76.5, 55.0, 8.9, 20.7. MS m/z (ra%): 315
(M1, 30), 248 (23), 246 (100), 243 (33), 182 (13), 180 (36), 167 (12). Analysis
calculated for: C14H9NO2CIF3; C, 53.27; H, 2.87; N, 4.44. Found: C, 52.90; H,
2.92; N, 4.77. L-(b)-dTTP and L-(b)-29,39-dideoxycytidine triphosphate (ddCTP)
were synthetized as described previously (13, 16). 39-Azido-29,39-dideoxythymi-
dine triphosphate (AZTTP) was from USB. Nevirapine was a gift from M. Botta
(University of Siena).
Nucleic acid substrates. The homopolymer poly(rA) (Pharmacia) was mixed
at weight ratios in nucleotides of 10:1 with the oligomer oligo(dT)12–18 (Phar-
macia) in 20 mM Tris-HCl (pH 8.0) containing 20 mM KCl and 1 mM EDTA,
heated at 65°C for 5 min, and then slowly cooled at room temperature. Prepa-
ration of d24:d66-mer deoxyoligonucleotide was as previously described (26).
Expression and purification of recombinant HIV-1 RT forms. Recombinant
RT, either wt or mutated, was expressed and purified to .95% purity as de-
scribed (25). Purified enzymes had the following specific activities on poly(rA) z
oligo(dT) (see below): HIV-1 p66(His)/p51, 75,670 U/mg; p66(L100I)/p51,
56,690 U/mg; p66(K103N)/p51, 96,415 U/mg; p66(Y181I)/p51, 65,770 U/mg. One
unit of DNA polymerase activity corresponds to the incorporation of 1 nmol of
dNMP into acid-precipitable material in 60 min at 37°C.
HIV-1 RT RNA- or DNA-dependent DNA polymerase activity assay. RNA-
dependent DNA polymerase activity of RT was assayed as follows. A final
volume of 25 ml contained buffer A (50 mM Tris-HCl [pH 7.5], 1 mM dithio-
threitol, 0.2 mg of bovine serum albumin per ml, 4% glycerol), 10 mM MgCl2. 0.5
mg of poly(rA) z oligo(dT)10:1 (0.3 mM 39-OH ends), 10 mM [3H]dTTP (1
Ci/mmol), and 2 to 4 nM RT. Reaction mixtures were incubated for 10 min at
37°C. Twenty-microliter aliquots were then spotted on glass fiber GF/C filters,
which were immediately immersed in 5% ice-cold trichloroacetic acid (TCA).
Filters were washed twice in 5% ice-cold TCA and once in ethanol for 5 min and
then were dried, and acid-precipitable radioactivity was quantitated by scintilla-
tion counting.
DNA-dependent DNA synthesis activity of RT was assayed in buffer A in the
presence of 0.3 mM (39-OH ends) of a d66-mer oligodeoxynucleotide corre-
sponding to nucleotides (nt) 1006 to 1071 of the sequence of the HIV-1 pol gene
(codons 169 to 190) annealed to a d24-mer complementary primer, 10 mM
concentrations each of dATP, dGTP, and dCTP, 10 mM [3H]dTTP (10 Ci/mmol),
and 2 to 4 nM RT. Reaction mixtures were incubated for 10 min at 37°C, and
reactions were stopped by addition of 5 ml of 0.4 M EDTA along with 200 mg of
salmon sperm carrier DNA. Twenty-microliter aliquots were then spotted on
glass fiber GF/C filters, which were immediately immersed in 5% ice-cold TCA.
Filters were washed twice in 5% ice-cold TCA and once in ethanol for 5 min and
then were dried, and acid-precipitable radioactivity was quantitated by scintilla-
tion counting
Inhibition assays. Reactions were performed under the conditions described
for the RNA- or DNA-dependent DNA synthesis activity of RT. Incorporation
of radioactive dTTP into poly(rA) z oligo(dT) or d24:d66-mer at different con-
centrations of DNA or dNTPs was monitored in the presence of increasing
amounts of inhibitors, either alone or in combination at fixed molar ratios. Drugs
combinations were as follows (fixed molar ratios [M]/[M]): [NVP]/[ddTTP],
1.5:1; [EFV]/[AZTTP], 5:1; [NVP]/[L-(b)-dTTP], 1:140; [EFV]/[L-(b)-dTTP],
1:1,400; [EFV]/[L-(b)-ddCTP] and [EFV]/[D-(b)-ddCTP], 1:550; [NVP]/[EFV],
20:1 for wt RT (RTwt), 200:1 for L100I; [AZTTP]/[EFV]/[NVP], 1:4:12.5.
Determination of synergy. The terms of agent interactions have been defined
in different ways. In the present work, the consensus terminology established at
the Fifth International Conference on the Combined Effects of Environmental
Factors was used (17). Analysis of the interaction between two agents, both
effective individually, has been performed according to the null reference mode
of Loewe additivity (24). Inhibitors were combined at fixed molar ratios depend-
ing on their different potencies in order to ensure that all the compounds
significantly contributed to the inhibition observed. Interaction indexes were
derived according to earlier guidelines (3). The cases in which the observed
effects were either significantly more or less than those predicted by the refer-
ence model for additivity were considered synergism or antagonism, respectively.
These corresponded to interaction index (I) values of ,1 for synergism or of .1
for antagonism.
The method was based on the additivity model originally developed by Loewe
and Muischnek (24) and successively implemented by Greco et al. (18). Dose-
response curves for drug action were assumed to follow the model originally
developed by Hill (20), adapted following the guidelines of Greco et al. (18), and
were generated by fitting the experimental data to the equation
E 5
EconS ID50D
m
1 1 S ID50D
m (1)
where E is the observed effect (% of activity), Econ is the control effect (activity
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in the absence of the inhibitor), and D50 is the concentration of inhibitor giving
50% inhibition.
The parameter m is the sigmoidicity term. The validity of the assumption of
the Hill model for dose-response curves was tested by calculating the Ki values
for each inhibitor according to a fully competitive (NRTI) or noncompetitive
(NNRTI) mechanism (11). The Ki values were then compared with the respective
D50 values calculated by equation 1, according to the relationships Ki 5 D50 for
the noncompetitive cases and Ki 5 D50/(11[S]/Km) for the competitive cases. In
all cases, optimal correlation was found between D50 and Ki values (not shown).
For the combination of two drugs at a fixed molar ratio (R 5 [drug1]/[drug2]),
D1 and D2 values were calculated from the D50 value derived from equation 1,
with (D1 1 D2) 5 D50 and D1 5 RD2.
Expected D1, D2, and Di values for the combination of i drugs under the null
reference hypothesis of no interaction were derived by inserting estimated D50
and m values for each drug in the combination in the specific form of the Loewe
additivity equation, which assumes that equation 1 is appropriate for each drug
individually (18).
1 5
D1
D50,1S EEcon 2 ED
1/m1 1
D2
D50,2S EEcon 2 ED
1/m2 1 . . . 1
Di
D50,iS EEcon 2 ED
1/mi
(2)
The null reference hypothesis of no interaction (equation 2) corresponded to I 5
1. It must be noted that inhibitory doses calculated according to equations 1 and
2 were designed with the symbol D, whereas the correspondent values derived
from equation 3 were indicated with the symbol ID. This was in order to be
consistent with the different method used for calculations. In all cases, D50 5
ID50.
Expected inhibitor concentrations at different fractional inhibitions were cal-
culated from the parameters D50, Econ, and m according to the equation
IDx 5 D50S EEcon 2 ED
1
m
(3)
where IDx is the dose of drug giving x% of inhibition. I was then calculated
according to Berenbaum (3) by the equation
I 5
D1
IDx1
1
D2
IDx2
1 . . . 1
Di
IDxi
(4)
where D1, D2, and Di were the concentrations of the drugs in combination, and
IDx1, IDx2, and IDxi are the predicted inhibitory concentrations of each drug
individually giving the observed effect of the combination. An I value of ,1
indicates synergy, .1 indicates antagonism, and 1 indicates additivity, according
to the Loewe additivity model.
All the analyses were based on the results of three independent experiments
for each drug combination, and the standard deviation values for each parameter
estimate are indicated. Values were calculated by non-least squares computer
fitting of the data to the appropriate equations. It has been shown that an
experimental factor affecting the relative potency (and also any observed syner-
gistic effect) of an NRTI is the number of possible incorporation sites along the
template to be replicated (37). For this reason, in order to study the effect of
NNRTIs in combination with AZTTP, a synthetic homopolymeric template,
poly(rA) z oligo(dT), in which the number of possible termination sites by
AZTTP incorporation was not limiting, was used. This approach allowed the
determination of the eventual synergism of AZTTP-NNRTI association without
any template-dependent effect. Synergistic combinations were then tested on a
more natural template, a heteropolymeric deoxyoligonucleotide substrate corre-
sponding to nt 1061 to 1071 of the HIV-1 pol gene, which is a sequence which is
physiologically replicated by HIV-1 RT. This template also possessed a nonlim-
iting number of possible incorporation sites for dideoxythymidine and -cytidine
nucleoside triphosphate analogs. In order to directly verify that the nature of the
substrate and/or the assay conditions did not affect the observed synergy, we have
tested a double combination of ddCTP and AZTTP against RTwt on the het-
eropolymeric template. As expected, this combination showed only an additive
effect, with I 5 0.97 (data not shown).
Statistical analysis. Equation 2 was used to estimate the expected values for
each drug in combination under the hypothesis of additivity. Mean values and
standard deviations for observed and expected value data sets were calculated,
and a Student’s t test was then conducted under the hypothesis that both mean
values were equal. Successively, a modification of the method of Drewinko et al.
(12) was used as an additional approach. Difference scores were calculated by
subtracting expected from observed values for each drug. Mean difference score
values and standard deviations for each drug were calculated, and a Student’s t
test was performed to test the hypothesis that the true mean value of the
differences between observed and expected data sets was zero. As an example,
observed and expected values for the efavirenz-AZTTP combination against
RTwt, along with statistics, are listed in Table 2. Both approaches were consistent
with significant synergy (P , 0.05). All the combinations which showed I values
of ,1 were analyzed in the same way, and significant synergy (P , 0.05) was
found in all cases.
RESULTS
Dose-response curve determination and calculation of effec-
tive inhibitory doses of individual drugs for RTwt and mutants.
In order to analyze the effects of multiple drug combinations
on the catalytic activity of HIV-1 RT, each drug was first tested
individually against either RTwt or the three mutant forms
L100I, K103N, and Y181I, containing known NNRTI resis-
tance mutations (described in Materials and Methods). The
corresponding inhibitory doses for E 5 10, 50, and 90% of the
control activity (ID90, ID50, and ID10, respectively) were calcu-
lated according to equation 3. The computed ID50 values are
listed in Table 1. The selected mutants showed, as expected,
significant resistance to NNRTIs, but the dose-response be-
havior was different. For example, the mutant L100I showed
maximal resistance to nevirapine at low inhibitory doses (ID10
of L100I [ID10L100I]/ID10 of wt [ID10wt] 5 85), which, however,
dropped at high inhibitory doses (ID90L100I/ID90wt 5 9), while
all the mutants tested were increasingly resistant to efavirenz
as the inhibition increased, with K103N showing the lowest
sensitivity to the drug compared to RTwt (ID10K103N/ID10wt 5
9.8; ID90K103N/ID90wt 5 59). On the other hand, none of the
mutants tested showed significant resistance to the triphos-
phate forms of D- or L-(b)-NRTIs, in agreement with previous
observations (25, 26).
Statistical analysis. According to equation 4, a combination
was considered synergistic when the observed effective inhib-
iting concentrations for each drug were significantly lower than
the corresponding values predicted by equation 2 under the
null reference hypothesis of additivity. Thus, a critical point to
address was whether the observed differences were statistically
significant. As an example, observed and expected values for
the efavirenz-AZTTP combination against RTwt, along with
statistics, are listed in Table 2. Two different approaches were
used, as described in Materials and Methods, and both were
found to be consistent with significant synergy (P , 0.05). All
the combinations which showed I values of ,1 were analyzed
in the same way, and significant synergy (P , 0.05) was found
in all cases.
Double and triple NNRTI–D-(b)-NRTI combinations show
synergism in the inhibition of RTwt. The effects of the nevi-
rapine-ddTTP, efavirenz-AZTTP, and nevirapine-efavirenz-
AZTTP combinations were tested on RTwt, and the interaction
parameters at 10, 50, and 90% inhibition were determined as
outlined in Materials and Methods. The calculated values are
listed in Table 3. All the combinations were found to be sig-
nificantly synergistic at inhibition doses of $50%; however, the
efavirenz-AZTTP combination displayed an already-high de-
gree of synergy at 50% inhibition. According to the Loewe
additivity model, the expected D1 and D2 values for two drugs
acting independently can be calculated from equation 2 and
corresponded to I 5 1. Under the experimental conditions
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used for efavirenz and AZTTP (molar ratio of 5:1), the ex-
pected values in the case of additivity at 50% inhibition would
be 33 nM for efavirenz and 6.6 nM for AZTTP (see Materials
and Methods). Comparison with the actual values derived
from the experimental data showed that both drugs had com-
parable reductions of their effective concentrations, thus
equally contributing to the observed synergism. A similar anal-
ysis for the nevirapine-ddTTP combination (molar ratio of
1.5:1) gave expected D1 and D2 values of 0.25 mM for nevirap-
ine and 0.1 mM for ddTTP. In this case, the contribution of
nevirapine to the observed synergy was more significant than
that of ddTTP, since the observed value was 2.5-fold lower
than that expected in the case of nevirapine but only 1.3-fold in
the case of ddTTP. For the triple combination, expected D1,
D2, and D3 values under the hypothesis I 5 1 were 6 nM for
AZTTP, 24 nM for efavirenz, and 75.1 nM for nevirapine.
Thus, as for the efavirenz-AZTTP combination, the three
drugs equally contributed to the observed synergy. The triple
AZTTP-efavirenz-AZTTP combination was also tested on a
heteropolymeric deoxyoligonucleotide substrate correspond-
ing to nt 1061 to 1071 of the HIV-1 pol gene, which is a
sequence which is physiologically replicated by HIV-1 RT. This
was done in order to directly verify that the nature of the
substrate and/or the assay conditions did not affect the ob-
served synergy. As reported in Table 3, the combination also
showed comparable synergy (I 5 0.68) on this template, indi-
cating that neither the RNA-DNA versus DNA-DNA struc-
ture nor the homopolymeric versus the heteropolymeric nature
of the template affected the observed synergy.
L-(b)-dideoxy but not L-(b)-deoxy-nucleoside triphosphate
analogs show synergistic effects in double NNRTI-NRTI com-
binations against RTwt and the NNRTI-resistant mutant
forms L100I, K103N, and Y1811. The combination efavirenz-
AZTTP was also tested against NNRTI-resistant mutants of
HIV-1 RT. The calculated interaction indexes are listed in
Table 3. The combination showed synergism towards all the
mutants tested, even though in the case of the K103N and
Y181I mutants significant synergism was observed only at in-
hibition doses of $90%. Expected values under the null ref-
erence model of Loewe additivity for the absence of interac-
tion at 50% inhibition were AZTTP 5 8.3 nM and efavirenz 5
41 nM for L100I, AZTTP 5 33 nM and efavirenz 5 169 nM
for K103N, and AZTTP 5 16 nM and efavirenz 5 82 nM for
Y181I. Comparison of the expected values with the observed
ones listed in Table 3 indicated that in all cases both drugs
were contributing equally to the observed synergy, with the
exception of K103N, where the potentiation was at the level of
efavirenz inhibition. The efficacy of the nevirapine–L-(b)-
dTTP, efavirenz–L-(b)-dTTP, efavirenz–D-(b)-ddCTP, and
efavirenz–L-(b)-ddCTP combinations was tested against
HIV-1 RTwt. Calculated values are listed in Table 4. Only the
combinations with either D-(b)- or L-(b)-ddCTP proved to be
significantly synergistic, even though at inhibition doses of
$90%. The L-(b)-ddCTP combination was also synergistic to-
wards the mutant L100I.
Double NNRTI–NNRTI combinations show different syner-
gistic effects against wt and L100I mutant RT. The effects of a
combination of nevirapine and efavirenz on HIV-1 RTwt and
the mutant L100I were assayed. Calculated values are listed in
Table 5. The combination proved to be synergistic for both
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enzymes at inhibition doses of $50%. Under the hypothesis of
no interaction (I 5 1), expected values at 50% inhibition ac-
cording to the Loewe additivity model were 16.3 nM for efa-
virenz and 0.33 mM for nevirapine in the case of RTwt and 29
nM for efavirenz and 5.8 mM for nevirapine in the case of the
L100I mutant. Comparison with the observed values reported
in Table 5 showed that in the case of RTwt, the observed
synergy was almost exclusively due to a twofold potentiation of
the effect of nevirapine, whereas in the case of the mutant
L100I both drugs contributed equally.
RTwt and NNRTI-resistant mutant RT have different sensi-
tivities to double NRTI-NNRTI combinations. One of the dis-
advantages in using Berenbaum’s interaction index for deter-
mining synergy is the difficulty of deriving a quantitative
measure of the intensity of the interaction from the different
calculated values of I (18). This is, however, a crucial point for
the evaluation of the relative efficacy of multiple drug combi-
nations against mutant forms of RT. Thus, in order to compare
the efficacy of different combinations, a plot of the uninhibited
fraction (fu 5 % of the control activity Econ) versus the calcu-
lated inhibitory doses (IDx) derived from experimental data for
each combination according to equation 3 was constructed. In
Fig. 1A the plot relative to the AZTTP-efavirenz combination
is shown. It was evident that different mutations conferred
increasing degrees of resistance to the synergistic combination
in all cases. When the effects of the efavirenz–L-(b)-ddCTP
combination against RTwt and mutant L100I were compared,
again the mutant displayed a degree of resistance which was
proportional to its resistance to efavirenz alone, even if the
combination proved to be synergistic (not shown).
AZTTP can reduce the level of resistance to efavirenz of the
K103N mutant RT. In Fig. 1B, the relative resistance values
(D50mut/D50wt) of each mutant to the combination were com-
pared with the corresponding values for AZTTP and efavirenz
alone (Table 1). The sensitivity of each enzyme to the combi-
nation correlated very closely with its resistance to efavirenz. A
relevant exception was the mutant K103N, which was twofold
more sensitive to the combination than to efavirenz alone with
respect to RTwt. As shown in Table 1, none of the mutants was
significantly resistant to AZTTP inhibition.
The sensitivity to double NNRTI-NNRTI combinations is
different between wt and L100I mutant RT. In the above dis-
TABLE 2. Comparison of observed and expected values and statistical analysis of the synergistic inhibition of the synthetic activity of wt
HIV-1 RT by the efavirenz-AZTTP combination
Ea (%)
and
statistics
Mean (nM) 6 SDb
Dobs-exp[EFV] Dobs-exp[AZTTP]
[EFV]obs for D1 [EFV]exp for D1 [AZTTP]obs for D2 [AZTTP]exp for D2
10 1.4 6 0.2 0.48 6 0.01 0.28 6 0.01 0.094 6 0.002 0.92 0.18
20 3.1 6 0.02 2.5 6 0.01 0.62 6 0.05 0.5 6 0.02 0.6 0.12
30 5.36 6 0.01 7.83 6 0.01 1.07 6 0.01 1.56 6 0.01 22.47 20.49
40 8.33 6 0.01 17.22 6 0.2 1.67 6 0.02 3.44 6 0.02 28.89 21.77
50 12.5 6 0.02 32 6 0.3 2.5 6 0.05 6.4 6 0.02 219.5 23.9
60 18.75 6 0.05 51.6 6 0.2 3.75 6 0.01 10.32 6 0.5 232.85 26.57
70 29.1 6 0.02 80.8 6 0.1 5.8 6 0.02 16.16 6 0.1 251 210.36
80 50 6 0.5 136.5 6 0.6 10 6 0.1 27.3 6 0.2 286.5 217.3
90 112.5 6 0.2 254 6 0.8 22.5 6 0.2 50.8 6 0.6 2141.5 228.3
Statisticsc m1 5 26.78 6 35.6 m2 5 64.77 6 83.6p m1 5 5.35 6 7.12 m2 5 12.95 6 16.7p m 5 237.9 6 48.3 m 5 27.59 6 8.6p
a E, observed inhibition expressed as percent of control activity without drugs (Econ).
b EFV, efavirenz; obs, observed effective concentration, calculated according to equation 3; exp, expected effective concentration under the null reference hypothesis
I 5 1, calculated according to equation 2. Dobs-exp, change between observed and expected values. D1 and D2, dose of drug 1 and drug 2 giving the indicated percentage
of inhibition of RT activity when tested in the combination (D1 1 D2).
c m, mean value; p, P , 0.05 compared to the observed value. This P value indicates that the probability that the observed value differ from the expected ones is $95%.
Thus, the observed synergy can be considered highly significant. For details see the text.
TABLE 3. Interaction parameters (I10, I50, I90) for 10, 50, and 90% inhibition of DNA synthesis of wt and
mutant HIV-1 RT by combinations of NNRTIs and D-(b)-NRTIsa
RT Drug (d1-d2-d3)b
Mean 6 SD
Econ (%) D1 (nM) D2 (nM) D3 (nM)
I
10 50 90
wt EFV-AZTTP 83 6 5 12.5 6 0.1 2.5 6 0.1 0.39 6 0.01
wt NVP-ddTTP 100 6 7 100 6 20 75 6 1 1.2 6 0.1 0.54 6 0.02 0.45 6 0.01
wt EFV-NVP-AZTTPc 101 6 5 15 6 2 50 6 5 4 6 1 0.7 6 0.1 0.62 6 0.02 0.46 6 0.02
91 6 7 60 6 5 180 6 7 15 6 1 0.68 6 0.05
L100I EFV-AZTTP 93 6 5 18 6 0.1 4.7 6 0.1 0.9 6 0.1 0.54 6 0.02 0.45 6 0.01
K103N EFV-AZTTP 94 6 5 118 6 2 34 6 0.5 1.5 6 0.1 0.97 6 0.02 0.81 6 0.01
Y181I EFV-AZTTP 90 6 5 73 6 5 18.7 6 0.1 1.2 6 0.1 0.74 6 0.02 0.65 6 0.01
a I10, I50, and I90, interaction index at 10, 50, and 90% inhibition of RT activity, respectively; Econ, estimated parameter for the control effect in the absence of the
drug; D1, D2, and D3, dose of inhibitors giving 50% inhibition of RT activity when tested in the combination (D1 1 D2 1 D3). For details see Materials and Methods.
b EFV, efavirenz; NVP, nevirapine. d1, d2, and d3, drugs 1, 2, and 3 in the combination.
c Data on the first line are for the drug combination on poly(rA) z oligo(dT), and data on the second line are for the combination on d24:d66-mer oligodeoxynucle-
otide.
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cussed cases, each enzyme was resistant to only one of the two
drugs used for the combination. A case in which the mutant
enzyme was resistant to both drugs in the combination was also
analyzed. Figure 2A shows the fu versus IDx plot for the inhi-
bition of RTwt and mutant L100I by the efavirenz-nevirapine
combination. This association proved to be synergistic with
both enzymes; however, the mutant L100I displayed a signifi-
cant resistance. The relative resistance of the L100I mutant at
50% inhibition was 20-fold to nevirapine and 1.5-fold to efa-
virenz when the inhibitors were tested individually and 26-fold
to their combination. However, at 90% inhibition, the relative
resistance values to nevirapine and efavirenz individually were
6-fold and 3.5-fold. respectively, whereas for the combination
the resistance increased up to .100-fold.
Comparison of double versus triple NRTI-NNRTI combina-
tions. In Fig. 2B, the double combinations efavirenz-AZTTP
and nevirapine-efavirenz were compared to the triple nevirap-
ine-efavirenz-AZTTP combination. The plot indicated that the
triple combination was more advantageous with respect to the
nevirapine-efavirenz association than the efavirenz-AZTTP as-
sociation. Indeed, when the D1 and D2 values listed in Table 3
and Table 5 for each double combination are compared to the
D1, D2, and D3 values listed in Table 3 for the triple combina-
tion, it can be seen that efavirenz and AZTTP doses required
to achieve 50% inhibition in all the combinations were similar,
whereas the nevirapine dose was decreased by threefold in the
triple versus the double combination.
DISCUSSION
As a first step towards the elucidation of the nature of the
interactions between different anti-HIV RT drugs, associations
between NRTIs and NNRTIs have been tested in in vitro
assays against RTwt and compared to three RT forms contain-
ing clinically relevant NNRTI resistance mutations, namely
L100I, K103N, and Y181I. We tested combinations of clinically
used NNRTIs (nevirapine and efavirenz) with either AZTTP
(the most widely used NRTI) or other model nucleoside ana-
logs (ddTTP and ddCTP). In particular, both D-(b)- and L-(b)-
dCTPs were compared for their ability to act synergistically in
combination with efavirenz. In this study, the inhibitory activity
of individual doses of the combined drugs was found to differ
significantly in additive versus synergistic associations. Syner-
gisms among inhibitors could be due to an increase of the
affinity of the enzyme for one or more of the components of
the associations with respect to the case of simple additivity.
Synergism can also occur among drugs acting on the same
binding site but specific for different enzyme-substrate inter-
mediates (10, 14, 28). When the median effective doses (D50)
for the different combinations tested were dissected into the
individual contributions of each drug and these latter values
were compared with the expected corresponding values for the
single agents in the combination under the hypothesis of no
interaction, the results showed that synergy of a combination
was not always equally influenced by the individual agents. For
example, the synergy of combinations including nevirapine
with either ddTTP or efavirenz resulted almost exclusively
from potentiation of the effects of nevirapine with respect to
the ones expected under the hypothesis of additivity. Thus,
optimizing synergistic interactions would also require the ra-
tional choice of agents to be associated. Moreover, the same
drug could behave differently when included in double versus
triple combinations. The relative contribution of nevirapine to
the observed synergy of the triple efavirenz-nevirapine-
TABLE 4. Interaction parameters (I10, I50, I90) for 10, 50 and 90% inhibition of DNA synthesis of wt and
mutant HIV-1 RT by combinations of NNRTIs and L-(b)-NRTIsa
RT Drug (d1-d2)b
Mean 6 SD
Econ (%) D1 (mM) D2 (mM)
I
10 50 90
wt NVP–L-dTTP 95 6 7 0.25 6 0.02 34.5 6 0.1 0.94 6 0.02
wt EFV–L-dTTP 103 6 5 0.03 6 0.005 44.5 6 0.5 1.1 6 0.01
wt EFV–L-ddCTP 91 6 0.5 0.013 6 0.001 7 6 0.5 0.96 6 0.02 0.62 6 0.01
wt EFV–L-ddCTP 101 6 5 0.016 6 0.001 8.95 6 0.05 1.2 6 0.1 0.97 6 0.02 0.66 6 0.01
L100I EFV–L-ddCTP 93 6 5 0.05 6 0.001 26.3 6 0.1 1.1 6 0.1 0.88 6 0.02 0.75 6 0.01
a I10, I50, and I90, interaction index at 10, 50, and 90% inhibition of RT activity, respectively; Econ, estimated parameter for the control effect in the absence of the
drug; D1 and D2, dose of inhibitors giving 50% inhibiton of RT activity when tested in the combination (D1 1 D2). For details see Materials and Methods.
b NVP, nevirapine; EFV, efavirenz; d1 and d2, drugs 1 and 2 in the combination.
TABLE 5. Interaction parameters (I10, I50, I90) for 10, 50, and 90% inhibition of DNA synthesis of wt and
L100I mutant HIV-1 RT by combinations of different NNRTIsa
RT Drug(d1-d2)b
Mean 6 SD
Econ (%) D1 (mM) D2 (mM)
I
10 50 90
wt NVP-EFV 103 6 5 0.16 6 0.02 0.02 6 0.005 1.2 6 0.1 0.72 6 0.02 0.26 6 0.02
L100I NVP-EFV 93 6 5 4.2 6 0.1 0.023 6 0.002 0.9 6 0.1 0.72 6 0.02 0.15 6 0.01
a I10, I50, and I90, interaction index at 10, 50, and 90% inhibition of RT activity, respectively; Econ, estimated parameter for the control effect in the absence of the
drug; D1 and D2, dose of inhibitors giving 50% inhibition of RT activity when tested in the combination (D1 1 D2). For details see Materials and Methods.
b NVP, nevirapine; EFV, efavirenz. d1 and d2, drugs 1 and 2 in the combination.
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AZTTP combination was comparable to those of the other two
drugs, but as shown in Fig. 2B, inclusion of AZTTP in the
combination was clearly advantageous over the double efa-
virenz-nevirapine association, since the absolute potency (i.e.,
effective inhibiting dose) of nevirapine was potentiated with
respect to its association with efavirenz only. In agreement with
published data, nevirapine was not found to inhibit HIV-1 RT
synergistically in combination with AZTTP only (36, 38), and
AZTTP only showed an additive effect when combined with
ddCTP, as expected (38) (data not shown). By comparison of
the potencies of different drug associations against drug-resis-
tant viral isolates in infected-cell-based assays, it has been
shown that the reduced susceptibility to a drug may affect the
synergistic effect of combinations containing that drug (8). The
same effect was also evident in our experimental approach. In
fact, it appeared that resistance mutations towards one or
more of the agents utilized can influence the efficacy of the
combination. As shown in Fig. 1, in general the absolute de-
gree of resistance of each mutant enzyme to the different
double drug combinations correlated with their relative resis-
FIG. 1. Resistance of wt and three mutant HIV-1 RTs to different combinations of NNRTIs and NRTIs. Dose-response curves for RTwt and
mutants have been generated, as outlined in Materials and Methods, by fitting experimental data to equation 2 and then calculating the respective
inhibition doses (IDx) at different x (%) of inhibition according to equation 3. (A) Dose-response curves for the combination of efavirenz (EFV)
and AZTTP. The fraction of uninhibited activity (fu 5 %Econ) has been plotted versus the calculated IDx for RTwt (circles), L100I (squares), Y181I
(triangles), and K103N (rhombics). Calculated parameters: (D1 1 D2)wt 5 15 nM; mwt 5 20.79; (D1 1 D2)L100I 5 22.7 nM, mL100It 5 21.17; (D1 1
D2)Y1811 5 91.7 nM, mY1811 5 21.49; (D1 1 D2)K103N 5 172 nM, mK103N 5 23.95. (B) Comparison of the relative resistance values (D50mut/D50wt)
of different mutant RT enzymes towards efavirenz and AZTTP either individually or in combination. D50 values for the combination were
calculated from the dose-response curves shown in panel A, whereas the correspondent values for the single drugs were derived from Table 1.
1198 MAGA ET AL. ANTIMICROB. AGENTS CHEMOTHER.
tance to the individual agents in the combination. However, for
the AZTTP-efavirenz combination, the mutant K103N showed
a level of resistance to the double combination which was
twofold lower than its resistance to efavirenz alone, suggesting
that in the presence of AZTTP, the sensitivity of the K103N
mutant to efavirenz was increased. These data indicated that a
synergistic combination could improve the sensitivity profile to
the single drugs utilized. In all cases when the RT mutant was
resistant to only one of the drugs utilized, the relative contri-
bution of each individual agent to the observed synergy with
the mutant enzymes was comparable to that observed with the
wild-type enzyme (Table 3 and 4). On the other hand, for the
efavirenz-nevirapine combination against the mutant L100I,
which was resistant to both drugs, contribution of efavirenz to
the observed synergy was also evident, contrary to the case of
RTwt, where the major contribution was attributable to nevi-
rapine only (Table 5). The recently reported inhibition of dif-
ferent enzyme-substrate complexes by efavirenz (28) provides
a molecular explanation for the observed synergy between this
compound and nevirapine. Moreover, the fact that additional
potentiation of nevirapine inhibition was gained by adding
AZTTP in the combination provided direct biochemical evi-
dence of the advantage of using triple versus double drug
combinations. The L-(b)-cytidine analog 3TC has become an
important component of combined anti-HIV drug therapy in
association with efavirenz. Other L-(b)-enantiomers of NRTIs
are currently being evaluated as potential antiviral agents;
however, little is known about the influence of the L-(b)- con-
figuration in determining the kind of interaction (whether syn-
ergistic, additive, or antagonistic) with currently used antiret-
roviral agents. The data presented showed that L-(b)-
enantiomers of NRTIs were synergistic when combined with
NNRTIs, as in the case of the combination of D-(b)- or L-(b)-
ddCTP with efavirenz, which showed comparable synergy
against RTwt. L-(b)-ddCTP was also synergistic in combination
with efavirenz towards the L100I mutant. The results of a
clinical study showed an advantage of the efavirenz-AZT-3TC
combination therapy over an indinavir-AZT-3TC combination
in suppressing viral replication in infected patients (32). The
observed synergy of efavirenz in inhibiting HIV-1 RT when
combined with D- and L-(b)-NRTIs might provide an explana-
tion for such a difference. Synergy, however, was observed in
the case of L-(b)-dideoxy- but not with L-(b)-deoxynucleoside
triphosphate analogs [compare the I values for L-(b)-dTTP
with the ones for L-(b)-ddCTP], confirming the advantage of
using dideoxy- versus deoxy-L-(b)-NRTIs (26, 27). In conclu-
sion, the presented approach was found to reliably reflect pre-
vious observations made with infected-cell-based assays. More-
over, the use of purified enzymes and defined in vitro systems
proved to be suitable for detailed kinetic studies of drug-drug
interactions. The data indicated that (i) the synergy of a com-
bination was not always equally influenced by the individual
agents utilized, (ii) a synergistic combination could improve
the sensitivity profile of a drug-resistant mutant enzyme to-
wards the single agents utilized, (iii) L-(b)-enantiomers of NR-
TIs were synergistic when combined with NNRTIs, and (iv)
inter- and intracombination comparisons of the relative poten-
cies of each drug could be used to highlight the different
contributions of each drug to the observed synergy.
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FIG. 2. (A) Resistance of wt and mutant L100I HIV-1 RT to combinations of two different NNRTIs. Dose-response curves for RTwt and
mutants have been generated, as outlined in Materials and Methods, by fitting experimental data to equation 2 and then calculating the respective
inhibition doses (IDx) at different x (%) of inhibition according to equation 3. The fraction of uninhibited activity (fu 5 %Econ) has been plotted
versus the calculated IDx for the combination of efavirenz (EFV) and nevirapine (NVP) against RTwt (circles) and L100I (squares). Calculated
parameters: (D1 1 D2)wt 5 0.18 mM, mwt 5 20.79; (D1 1 D2)L100I 5 4.2 mM, mL100It 5 20.5. (B) Efficacy of triple versus double RT inhibitor
combinations on wt HIV-1 RT. Dose-response curves for RTwt and mutants have been generated, as outlined in Materials and Methods, by fitting
experimental data to equation 1 or 2 and then calculating the respective inhibition doses (IDx) at different x (%) of inhibition according to equation
3. The fraction of uninhibited activity (fu 5 %Econ) has been plotted versus the calculated IDx for RTwt (circles) for the combinations EFV-NVP
(squares), EFV-AZTTP (circles), and EFV-NVP-AZTTP (triangles). Calculated parameters: (D1 1 D2)EFV-AZTTP 5 15 nM, mEFV-AZTTP 5 21;
(D1 1 D2)EFV-NVP 5 0.18 mM, mEFV-NVP 5 20.8; (D1 1 D2 1 D3)EFV-NVP-AZTTP 5 69 nM, mEFV-NVP-AZTTP 5 20.9.
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